Current Report Filing (8-k)
08 April 2015 - 10:15PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 6, 2015
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA |
|
000-54767 |
|
46-3259117 |
(State
or other jurisdiction of
incorporation
or organization) |
|
Commission
file number |
|
(IRS
Employer
Identification
No.) |
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(323)
424-3169
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM
5.02 COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On
April 6, 2015, the Rich Pharmaceuticals, Inc. (the “Company”) Board of Directors granted Ben Chang options to purchase
50,000,000 shares of Company common stock under the Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan, as amended.
The options have an exercise price of $.0008 per share; a term of 5 years; are immediately vested; and may be exercised by cashless
exercise. Ben Chang is the Chief Executive Officer and a director of the Company.
ITEM
8.01 OTHER EVENTS
On
September 6, 2013, the Company’s Board of Directors approved the adoption of the Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock
Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid the Company in recruiting and retaining key employees,
directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other
stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants of
the Company and its affiliates are eligible to participate under the 2013 Plan.
On
April 6, 2015, the Company’s Board of Directors approved an amendment to the 2013 Plan to increase the number of shares
reserved for awards under the 2013 Plan from 90,004,800 shares to 390,004,800 shares. The foregoing is only a brief description
of the material terms of the 2013 Plan Amendment No. 2, and does not purport to be a complete description of the 2013 Plan Amendment
No. 2, and such description is qualified in its entirety by reference to the 2013 Plan Amendment No. 2 which is filed as an exhibit
to this Current Report.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
Dated:
April 8, 2015 |
|
|
|
By: |
|
/s/ Ben
Chang |
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer |
RICH
PHARMACUETICALS, INC.
2013
EQUITY INCENTIVE PLAN AMENDMENT NO. 2
April
6, 2015
WHEREAS,
Rich Pharmaceuticals, Inc., a Nevada corporation (the "Corporation"), has adopted the 2013 Equity Incentive Plan
(the “2013 Plan”) and reserved 60,004,800 shares of the Corporation's common stock (the "Shares")
under the 2013 Plan;
WHEREAS,
on October 6, 2014, pursuant to the terms of the Plan, the Board of Directors approved an amendment to the 2013 Plan to increase
the amount of shares reserved for issuance to a total of 90,004,800 Shares;
WHEREAS,
on April 6, 2015, pursuant to the terms of the Plan, the Board of Directors approved an amendment to the 2013 Plan to increase
the amount of shares reserved for issuance to a total of 390,004,800 shares
NOW,
THEREFORE, the 2013 Plan is hereby amended to provide that the total number of Shares reserved for issuance under the 2013 Plan
is 390,004,800.
|
By: /s/ Ben Chang |
|
Ben Chang, CEO |